CPA
LENZ

Capital Performance Advisors’s LENZ Therapeutics LENZ Stock Holding History

Capital Performance Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6
Closed -$142 – 2792
2024
Q3 		$142 Buy
+6
New +$133 ﹤0.01% 2635

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Performance Advisors's LENZ Position: Q4 2024 in Review

Capital Performance Advisors sold out of LENZ Therapeutics (LENZ) in Q4 2024, closing a stake of 6 shares — an estimated $142 sold.

Capital Performance Advisors first reported a position in LENZ in Q3 2024 and held it in 1 quarter. The position peaked at $142 in Q3 2024. 94 funds tracked by Wall St. Rank hold LENZ as of Q4 2024.

  • Capital Performance Advisors reported no remaining LENZ Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 6 LENZ Therapeutics shares in Q4 2024, an estimated $142.
  • Capital Performance Advisors first reported a position in LENZ Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's LENZ Therapeutics position peaked at $142 in Q3 2024.
  • 94 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.